Biosimilars May Be Viable Only For Blockbuster Biologics, Study Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Report by economist Brill suggests that high development and compliance costs will limit the range of biosimilars that are developed. The study was funded by pharmacy benefit manager Prime Therapeutics.